About Promiliad Biopharma
Promiliad Biopharma is an innovative drug discovery company specializing in creating novel natural products. Our dedicated team of experts utilizes cutting-edge technologies and computational approaches to accelerate the development of safe and effective pharmaceutical solutions.
Committed to excellence and social responsibility, we aim to address unmet medical needs and contribute significantly to the advancement of healthcare worldwide through strategic partnerships and rigorous research.
Founded in 2002
Promiliad Biopharma was incorporated in 2002 to take advantage of collaborative projects between researchers at the University of Florida, Ohio University and The University of Montana.
The focus of the company has always been on the development of antibiotics in particular exploring how natural products can be exploited to generate new antibiotics.
Funding & Accomplishments
Promiliad has been very successful in obtaining NIH funding and has successfully discovered new types of natural product libraries which can be screened for antibiotic activity. We have also developed Bactrim analogs (successfully licensed).
Our Current Goals
Currently we’re focused on developing Natural Product Fragment Libraries as a way to synthetically generate very diverse sets of natural products for antibiotic testing.
Providing effective results in early stage, preclinical, and pre-IND testing.
We develop new antibiotics and design new approaches for the in-vitro evaluation of antibiotics
“Bad bugs, no drugs: As antibiotic research stagnates, a public health crisis brews” was the title of a policy report from the Infectious Disease Society of America published in 2004, a report which outlined the consequences of alarming rates of antibiotic resistance and the dire need for a reinvestment in the search for new antibiotics to overcome the exceedingly lean development pipeline. Updates in 2008 and 2013 showed that while some progress was being made the need for new compounds was still unmet. As very few drugs (linezolid, daptomycin, televancin, tigecycline) that are not analogs of well-established drugs have been introduced in the last twenty-five years the case for developing new antibiotic classes is a compelling one.